FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * HEBARD GEORGE   2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [ENZN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Interim PEO and Interim COO (Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC., 20 KINGSBRIDGE ROAD 3. Date of Earliest Transaction (Month/Day/Year) 11/07/2012 (Street) PISCATAWAY, NJ 08854 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock (1) 11/07/2012   A   24,500 (2) A $ 0 43,237 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy) (3)

$ 6.18

11/07/2012

A

73,500

(4)

11/07/2022

Common Stock

73,500

$ 0

73,500

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
HEBARD GEORGE C/O ENZON PHARMACEUTICALS, INC. 20 KINGSBRIDGE ROAD PISCATAWAY, NJ 08854	X		Interim PEO and Interim COO

Signatures

/s/ by Andrew Rackear, Attorney-in-Fact		11/08/2012
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Restricted Stock Units granted by the Issuer pursuant to the Issuer's 2011 Stock Option and Incentive Plan and qualified under Rule 16b-3(d). Each unit represents a contingent right to receive one share of the Issuer's Common Stock.
(2)	The Restricted Stock Units will vest in three (3) tranches. Of the 24,500 Restricted Stock Units granted, 8,166 will vest on November 7, 2013, 8,167 will vest on November 7, 2014 and 8,167 will vest on November 7, 2015, in each case if the Reporting Person remains employed by the Issuer on such date. The Restricted Stock Units do not have an expiration date.
(3)	Stock options granted by Issuer pursuant to the Issuer's 2011 Stock Option and Incentive Plan and qualified under Rule 16b-3(d).
(4)	The stock options will vest in four (4) tranches. Of the 73,500 stock options granted, 18,375 stock options will vest on November 7, 2013, 18,375 stock options will vest on November 7, 2014, 18,375 stock options will vest on November 7, 2015 and 18,375 stock options will vest on November 7, 2016, in each case if the Reporting Person remains employed by the Issuer on such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.